# Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer

> **NCT03335241** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 140 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Fludarabine and Pegylated liposomal doxorubicin
- **DRUG:** Pegylated liposomal doxorubicin

## Key facts

- **NCT ID:** NCT03335241
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-01
- **Primary completion:** 2021-12
- **Final completion:** 2022-12
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2017-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03335241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03335241, "Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03335241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*